ArticleHaematologica2024
Proteogenomic profiling uncovers differential therapeutic vulnerabilities between
Abstract readLetter
In one paragraph
Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Molecular Pathology of Blood Cancer: A Comprehensive Review of Chromosome and Genetic Abnormalities and Their Clinical Utility.British journal of biomedical science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Lena BlumelDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Flavia BernardiInstitut Curie, CNRS UMR, INSERM, PSL Research University, Orsay, France; CNRS UMR 3347, INSERM U1021, Universite Paris Sud, Universite Paris-Saclay, Orsay.
Daniel PicardDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Jacob Torrejon DiazInstitut Curie, CNRS UMR, INSERM, PSL Research University, Orsay, France; CNRS UMR 3347, INSERM U1021, Universite Paris Sud, Universite Paris-Saclay, Orsay.
Vera H JepsenDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Rebecca HasselmannDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Julian Schliehe-DiecksDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Jasmin BartlDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf, Germany; Group for Interdisciplinary Neurobiology and Immunology - INI-research, Institute of Zoology, University of Hamburg, Hamburg.
Nan QinDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Beat BornhauserDepartment of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zurich.
Sanil BhatiaDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Blerim MarovkaDepartment of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zurich.
Veronique MarsaudInstitut Curie, CNRS UMR, INSERM, PSL Research University, Orsay, France; CNRS UMR 3347, INSERM U1021, Universite Paris Sud, Universite Paris-Saclay, Orsay.
Florent DingliInstitut Curie, PSL Research University, Centre de Recherche, CurieCoreTech Spectrometrie de Masse Proteomique, Paris.
Damarys LoewInstitut Curie, PSL Research University, Centre de Recherche, CurieCoreTech Spectrometrie de Masse Proteomique, Paris.
Martin StanullaDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover.
Jean-Pierre BourqinDepartment of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zurich.
Arndt BorkhardtDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Marc RemkeDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; Division of Pediatric Neuro-Oncogenomics, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf.
Olivier AyraultInstitut Curie, CNRS UMR, INSERM, PSL Research University, Orsay, France; CNRS UMR 3347, INSERM U1021, Universite Paris Sud, Universite Paris-Saclay, Orsay.
Ute FischerDepartment of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Dusseldorf, Medical Faculty, and University Hospital Dusseldorf, Dusseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Dusseldorf, Dusseldorf. ute.fischer@med.uni-duesseldorf.de.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Oncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaBasic Helix-Loop-Helix ProteinsHumansPre-B-Cell Leukemia Transcription Factor 1ProteogenomicsTranslocation, GeneticBasic Helix-Loop-Helix ProteinsOncogene Proteins, FusionPre-B-Cell Leukemia Transcription Factor 1TCF3 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.